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Abstract 31 
Objectives: Overprescribing of antibiotics by general practitioners is seen as a major driver 32 
of antibiotic resistance. Training in communication skills and C-reactive protein (CRP) 33 
testing both appear effective in reducing such prescribing. This study assesses the cost-34 
effectiveness of (i) training general practitioners (GPs) in the use of CRP testing, (ii) training 35 
GPs in communication skills and (iii) training GPs in both CRP testing and communication 36 
skills compared to usual care.    37 
Methods: Economic analyses (cost-utility analysis (CUA) accounting for the cost of 38 
antibiotic resistance and cost-effectiveness analysis (CEA)) were both conducted from a 39 
health care perspective with a time horizon of 28 days alongside a multinational, cluster, 40 
randomised, factorial controlled trial in patients with respiratory tract infections in five 41 
European countries. The primary outcome measures were QALYs and percentage reductions 42 
in antibiotic prescribing. Hierarchical modelling was used to estimate an incremental cost-43 
per-QALY-gained and an incremental cost-per-percentage-reduction in antibiotic prescribing. 44 
Results: Overall, the results of both the CUA and CEA showed that training in 45 
communication skills is the most cost-effective. However, excluding the cost of antibiotic 46 
resistance in the CUA resulted in usual care being the most cost-effective option. Country-47 
specific results from the CUA showed that training in communication skills was cost-48 
effective in Belgium, UK and Netherlands whilst training in CRP was cost-effective in 49 
Poland.  50 
Conclusion: Internet-based training in communication skills is a cost-effective intervention 51 
to reduce antibiotic prescribing for respiratory tract infections in primary care if the cost of 52 
antibiotic resistance is accounted for.    53 
  54 
Introduction 55 
Antibiotic resistance is currently one of the world’s leading public health concerns, which 56 
places a heavy burden on scarce resources. In the UK, resistant infections such as MRSA are 57 
estimated to cost the National Health Service an additional £1 billion in extra treatments 58 
annually1 and without a resolution ‘superbugs’ are estimated to cause more deaths than 59 
cancer by 2050, costing about $100 trillion globally.2 60 
The difficulty in determining who will benefit from prescribing, and desire to satisfy patients 61 
demands, appear to be driving inappropriate and over-prescribing of antibiotics by general 62 
practitioners (GPs).3-5 As well as impacting upon the development of resistance, antibiotic 63 
prescribing is associated with significant costs.6 The National Health Service in the UK 64 
incurs an annual cost of between $35(£23) and $70(£47) million in antibiotic prescription 65 
costs for acute cough/lower respiratory tract infections alone for example.7 Reducing the 66 
inappropriate and over-prescribing of antibiotics would thus not only help reduce the problem 67 
of antibiotic resistance but also save scarce resources. 68 
The rate of development of new antibiotics has slowed down over the past three decades8-11 69 
and the antibiotics currently available must be conserved. One way to assist with this 70 
protection is to find cost-effective ways of changing prescribing behaviour of GPs.  71 
Interventions to reduce prescribing, based on persuasion, have generally been ineffective in 72 
dealing with the problem12-13, and so more recent focus has turned to training GPs in 73 
advanced consulting skills and using point of care tests. These have resulted in a change in 74 
their prescribing behaviour,14,15 with internet-based training programmes providing a 75 
reduction in antibiotic prescribing similar to the standardized methods of training.16 Such 76 
internet-based training was developed by the Genomics to combat Resistance against 77 
Antibiotics in Community-acquired LRTI in Europe (GRACE) consortium.4,17-18 The 78 
interventions consisted of (i) training GPs in the use of C-reactive protein testing (‘CRP’), (ii) 79 
training GPs in communication skills (‘communication skills’) and (iii) training GPs in both 80 
CRP testing and communication skills (‘combined’).  81 
Results from the GRACE INTRO trial indicates that all three of these interventions (i) CRP 82 
(ii) communication skills and (iii) combined are effective in changing GP antibiotic 83 
prescribing behaviour.19 However, in addition to the effectiveness of these interventions, it is 84 
important to determine whether the interventions provide value for money. One study 85 
conducted a cost-effectiveness analysis using reductions in antibiotic prescribing as an 86 
outcome measure and found all three interventions to be cost-effective compared with usual 87 
care.20 However, no study has assessed the cost-effectiveness of these interventions in a 88 
multinational setting or estimated the country-specific cost-effectiveness of these 89 
interventions. The aim of this study is to assess the cost-effectiveness of these interventions 90 
across five European countries.   91 
 92 
Patients and methods 93 
Patients and settings 94 
The economic analysis was conducted alongside a multinational, cluster, randomised, 95 
factorial controlled trial in which participating practices were randomised to one of four study 96 
groups (i) CRP, (ii) communication skills, (iii) combined and (iv) usual care.19 The 97 
perspective adopted was that of the health service, including costs to the health service and 98 
health care cost to the patient. Consenting participants who presented with respiratory tract 99 
infections were recruited from primary care networks across five countries in Europe: 100 
Belgium, Netherlands, Poland, Spain, and the United Kingdom (England and Wales). The 101 
study was approved by ethics committees in all countries and all eligible individuals provided 102 
written consent before participating in the study. Full details of the clinical trial and 103 
intervention have been published elsewhere.4,17-19  104 
 105 
Data collection 106 
Resource use 107 
The main sources of resource use information were the case report form (CRF) completed by 108 
primary care clinicians at the day of the consultation (day 1), and a diary completed by 109 
patients over a four-week period starting at day 1.  Resource use data were collected on the 110 
following: consultations with health professionals, use of medications (over-the-counter and 111 
on prescription), medical investigations and hospital admissions.   112 
 113 
Unit costs 114 
Unit costs specific to each participating country were obtained mainly from national and 115 
international sources. In cases where costs were not available, they were obtained from a 116 
study previously published by the authors.21 These costs were inflated to 2016 prices using 117 
the consumer price index for each country.22 Where unit costs were unavailable, a market 118 
basket approach23 was used to estimate a relationship between the UK and the country of 119 
interest to obtain this cost. The UK was chosen because all unit costs were available for this 120 
setting.  121 
Medications were classified into 13 different groups. As it was not feasible to obtain unit 122 
costs for each individual drug for each country, a cost was generated for each of the 13 123 
groups by estimating an average price from a list of drugs within that group. Table 1 gives a 124 
summary of the various sources of unit costs.  125 
Intervention costs 126 
For CRP, capital costs were obtained from the manufacturer (Orion Diagnostica) who quoted 127 
an average cost of €1,200. This cost was then annuitized assuming that the machine has a 128 
lifespan of three years, at an interest rate of 3.5%, and a cost-per-patient estimated. The costs 129 
of the reagents used (€7.45 (£6) per patient) were obtained from the provider (Oxford 130 
Biosystems).  131 
With respect to the communication skills, the cost of the booklet given to patients, €0.36 132 
(£0.29), was obtained from study coordinators and converted to country equivalent costs 133 
using the market basket approach.23 For the combined intervention, the cost of the CRP 134 
machine and the cost of booklet estimated above were included. 135 
To estimate the cost of the internet-based training, we obtained information on the amount of 136 
time GPs spent on it in each arm and estimated the total cost of time spent on training. This 137 
value was divided by the number of patients per GP to estimate the cost per patient. GPs 138 
spent on average 26.54 minutes, 37.44 minutes and 39.76 minutes on training in the CRP, 139 
communication skills and combined intervention arms respectively. Information on training 140 
has been published in a previous study.4 GPs also received face-to-face training in using the 141 
CRP device and a similar approach to that described above was used to estimate a cost per 142 
patient in each arm. All costs were converted to Euros using purchasing power parities. In 143 
addition to presenting costs in Euros, costs were also presented in Pounds Sterling. All costs 144 
are presented in 2016 prices.   145 
Previous research has highlighted the importance of including the cost of antibiotic resistance 146 
in economic evaluations assessing interventions in this area.24-25 As a result of this, cost of 147 
resistance figures generated from a recent study25 were added to every antibiotic prescription 148 
irrespective of the trial arm. The inclusion of these costs was limited to the cost-utility 149 
analysis since the outcome for the cost-effectiveness analysis (percentage reduction in 150 
antibiotic prescribing) indirectly accounts for antibiotic resistance given the fact that 151 
antibiotic prescribing leads to antibiotic resistance.   152 
Health outcomes 153 
Health outcomes were measured using the three-level version of the EQ-5D questionnaire. 154 
This instrument comprises five dimensions: mobility, self-care, usual activities, 155 
pain/discomfort and anxiety/depression, each with three levels: no problems, some problems 156 
and severe problems.26 Patients were asked to complete the EQ-5D-3L questionnaire over the 157 
entire four week period (at day 1, and at the end of weeks 1, 2, 3 and 4), or until they felt 158 
better.  EQ-5D-3L index scores were generated using the European Harmonised Tariff 27 and 159 
have been validated for use in respiratory disease.28  160 
Antibiotic prescribing 161 
Physicians were asked to state whether they prescribed an antibiotic and this information was 162 
used to estimate the rate of antibiotic prescribing in each of the trial arms.   163 
Statistical analysis 164 
The economic evaluation comprised two main analyses: a cost-utility analysis (CUA; cost per 165 
QALY gained) and a cost-effectiveness analysis (CEA; cost per percentage reduction in 166 
antibiotic prescribing). Both were carried out on an intention to treat basis. For each 167 
participant included in the study, a QALY score over the 4-week period was estimated using 168 
the area under the curve approach.29 Total healthcare costs over the 4-week period were 169 
calculated by multiplying the resource items used by the respective unit cost and summing 170 
over all items. Missing costs and health outcomes were imputed using a multiple imputation 171 
methodology. The technique used was predictive mean matching and the imputation model 172 
included 25 imputed datasets 30    173 
Multilevel modelling, recommended for the economic evaluation of cluster and multinational 174 
trials, was used for data analysis.31-32 Dependent variables included total cost, QALYs and 175 
antibiotic prescribing. The model controlled for day 1 EQ-5D, gender, age, smoking, sex, 176 
crepitations, wheeze, pulse rate higher than 100 beats per minute, temperature higher than 177 
37.8 degrees Celsius, respiratory rate, blood pressure and duration of cough. These variables 178 
were controlled for in order to adopt a similar approach to the clinical study. To explore 179 
country variation in the cost-effectiveness of the interventions, adjusted country-specific cost-180 
effectiveness estimates were also obtained using a Bayesian approach.33 Minimally 181 
informative prior distributions were placed on all model parameters.34 All analysis was 182 
carried out in STATA 12, Winbugs 14 and R statistical software. Model estimates of the 183 
difference in costs, QALYs and antibiotic prescribing were used to derive an incremental 184 
cost-per-QALY-gained and an incremental cost-per-percentage-reduction in antibiotic 185 
prescribing.  186 
For the CUA, we used the NICE recommended threshold of between £20,000 to £30,000 187 
(€24,655 to €36,928) per QALY to judge the cost-effectiveness of the interventions.35 188 
A ‘Within the table’ analysis was adopted to account for the factorial nature of the trial.36-37 189 
This method assumes that the interventions are not independent i.e. the costs and effects of 190 
communication skills are influenced by the inclusion of CRP testing and vice-versa. This 191 
approach, which considers each treatment option individually, was used for the base-case 192 
analysis. All interventions were ordered in terms of increasing cost, for costs, QALYs and 193 
percentage reduction in antibiotic prescribing for each treatment arm to be compared 194 
incrementally. The most cost-effective option was selected based on the principles of 195 
dominance (where an intervention is less costly and more effective than the appropriate 196 
comparator(s)) and extended (weak) dominance (where an intervention is ruled out if the 197 
Incremental cost-effectiveness ratio (ICER) is greater than that of a more effective 198 
intervention).38 In addition, all interventions were compared to usual care individually.  199 
Sensitivity analysis 200 
Sensitivity analysis had two main foci. First, the results were compared against country-201 
specific thresholds to determine whether the interventions are cost-effective. This analysis 202 
was limited to the CUA and of the five participating countries, only the UK has an explicit 203 
threshold (£20,000 (€24,655) to £30,000 (€36,928) per QALY gained.35 There is no explicit 204 
threshold in the Netherlands, Belgium, Spain and Poland. However, a value of  €20,000 per 205 
QALY gained is often used in the Netherlands,39 €35,000 per QALY gained has been used to 206 
inform decision making in Belgium40 and in Spain, it has been suggested that the threshold 207 
value should lie between €22000 and €25000 per QALY gained.41 These values were 208 
therefore used to represent cost-effectiveness thresholds in the countries mentioned. No 209 
threshold value was identified in Poland.  210 
Second, to further explore the impact of including the cost of resistance, sensitivity analysis 211 
focused on conducting the economic evaluation without accounting for the cost of antibiotic 212 
resistance. This analysis was limited to the CUA since the base case CUA included the cost 213 
of resistance. 214 
 215 
 216 
 217 
Results 218 
A total of 246 practices participated in the study and contributed 4264 participants across five 219 
European countries. The country contribution to sample size ranged from 318 (7.5%) in 220 
Belgium to 1419 (33.3%) in Poland (Table 1).  221 
Resource use and costs 222 
A breakdown of resource use items is presented in Table 2. Compared to the other 223 
interventions, visits to the GP and hospital admissions were lower in the usual care arm. 224 
Visits to the GP were highest in the CRP group, whilst visits to the nurse were highest in the 225 
communication skills group. As was expected, those in the CRP and combined intervention 226 
groups had more CRP tests performed. Approximately 59% of participants in the usual care 227 
arm had an antibiotic prescribed compared to approximately 34% in the combined 228 
intervention arm. Costs associated with resource use items are presented in Table 3. GP costs 229 
were highest in the CRP group whilst nurse costs were highest in the communication skills 230 
group. Costs associated with over-the-counter medication were highest in the usual care arm.  231 
Outcomes 232 
There was an improvement in health of participants over the 4-week period as shown by the 233 
EQ-5D scores. The scores at four weeks were higher than those at day 1 in all four treatment 234 
arms (Table 4). Overall, antibiotic prescribing was highest in the usual care group and lowest 235 
in the combined intervention group (Table 4).  236 
 237 
 238 
 239 
Cost-utility analysis 240 
The CUA results indicate that overall, communication skills is the most cost-effective 241 
intervention since it dominated all other interventions (Table 5). Compared to usual care, 242 
both communication skills and CRP were dominant whilst the combined intervention was 243 
dominated. Country-specific estimates showed that communication skills was the most cost-244 
effective intervention in Belgium, UK and Netherlands. CRP is only cost-effective in 245 
Netherlands if the threshold is above €27,000 (£21,903) per QALY gained. CRP is cost-246 
effective in Poland whilst usual care is cost-effective in Spain (Table 5 and Figures 1 and 2).  247 
Cost-effectiveness analysis 248 
With respect to the CEA (percentage reduction in antibiotic prescribing as an outcome), 249 
communication skills was associated with an ICER of €68.08 (£55.23) per percentage 250 
reduction in antibiotic prescribing when compared to usual care. The ICER for CRP 251 
compared to communication skills was €176.53 (£143.20) per percentage reduction in 252 
antibiotic prescribing and the ICER for the combined intervention compared to CRP was 253 
€338.89 (£274.90) per percentage reduction in antibiotic prescribing (Table 6). Compared to 254 
usual care, ICERs ranged from €68.08 (£55.23) per percentage reduction in antibiotic 255 
prescribing with communication skills to €126.21 (£102.38) per percentage reduction in 256 
antibiotic prescribing with the combined intervention. Country-specific estimates show that 257 
CRP is the most cost-effective intervention in Belgium. In the Netherlands, CRP is cost-258 
effective if society is willing to pay around €72 (£58) per percentage reduction in antibiotic 259 
prescribing. On the other hand, communication skills is the most cost-effective in Poland, 260 
Spain and the UK (Table 6 and Figures S1 and S2).  261 
 262 
Sensitivity analysis 263 
In terms of comparing the results to country-specific cost-effectiveness thresholds, 264 
communication skills was cost-effective in Belgium, Netherlands and UK, CRP was cost-265 
effective in Poland and Usual care was cost-effective in Spain (Table S1).  266 
The results of the sensitivity analysis which excludes the cost of antibiotic resistance are 267 
presented in Table S2, Figure S3 and Figure S4, and they show that, overall, usual care is 268 
cost-effective if the cost of antibiotic resistance is not accounted for. The country-specific 269 
estimates also show that, with the exception of Belgium where communication skills was 270 
cost-effective, usual care is the most cost-effective intervention in all other countries when 271 
the cost of antibiotic resistance is not included. 272 
 273 
Discussion 274 
Summary of main findings 275 
This study evaluated the cost-effectiveness of (i) training GPs in the use of CRP testing, (ii) 276 
training GPs in communication skills and (iii) training GPs in both CRP testing compared to 277 
usual care. In terms of cost-per-percentage reduction in antibiotic prescribing, overall, 278 
communication skills was the most cost-effective. Similarly, the CUA also showed that 279 
communication skills was the most cost-effective intervention. However, the country-specific 280 
estimates were not consistent across the CUA and the CEA. The only country where 281 
communication skills was cost-effective across both the CUA and CEA was the UK. 282 
Compared to usual care, both communication skills and CRP are cost-effective. Sensitivity 283 
analysis where the cost of resistance was not included in the CUA led to a scenario where 284 
usual care was the most cost-effective intervention overall.  285 
Strengths and limitations of the study 286 
There are several strengths to this study. First, the factorial nature of the study enabled the 287 
relative cost-effectiveness of four different interventions to be explored within the same trial. 288 
Second, this study utilized data from five different European countries and so the findings 289 
may be more generalisable than those obtained from previous studies conducted in single 290 
country settings. Third, the study presented country-specific cost-effectiveness estimates, 291 
and, fourth, this study explored the implications of accounting for antibiotic resistance in 292 
economic evaluations.  293 
There are also a number of limitations. First, this study is conducted alongside a 294 
multinational, cluster randomised, factorial controlled trial, which presents additional 295 
complexities with respect to the analysis of the data. The factorial nature has the effect of 296 
reducing the sample size for any of the interventions on its own and therefore increasing the 297 
degree of uncertainty in the economic data. In this study, randomisation took place at the 298 
cluster/practice level whilst health economics outcomes such as QALYs were measured at the 299 
level of the individual. However, this has been addressed using methods that account for the 300 
hierarchical nature of the data. Second, assumptions were required to estimate country-301 
specific unit costs where these were not available. Third, with respect to the CUA, since there 302 
is no European wide cost-effectiveness threshold, this study relied on the UK threshold to 303 
judge the cost-effectiveness of interventions. Other studies have also noted problems with 304 
regards to the choice of cost-effectiveness threshold in a multinational setting.42 Cost-305 
effectiveness thresholds used in the Netherlands and Spain are €20,000 and €24,000 per 306 
QALY gained respectively. Fourth, with respect to the CEA, there is no commonly accepted 307 
threshold at which achieving an amount of antibiotic prescribing would be considered cost-308 
effective. It is therefore difficult to reach a conclusion about the cost-effectiveness of the 309 
interventions based on an accepted threshold for the analysis. This study did not assess the 310 
long-term cost-effectiveness of the interventions under consideration. As a result of this, any 311 
long-term issues such as change in practice over time was not assessed. Finally, the use of 312 
estimates of the costs of antibiotic resistance is problematic given the difficulty of making 313 
such estimates. 314 
 315 
Comparison with other studies 316 
Other studies have reached similar conclusions about the cost-effectiveness of 317 
communication skills20 and CRP.20,43 This study therefore adds to the evidence about the 318 
potential benefits of CRP and communication skills, but for the first time in a rigorous 319 
experimental multinational context where the interventions have been assessed across a 320 
number of European countries. One previous study also concluded that ignoring the cost of 321 
antibiotic resistance in economic evaluations could lead to misleading conclusions,25 a result 322 
which is similar to what was found in this study.  323 
  324 
Policy implications and implications for future research 325 
The results of this study indicate that communication skills is cost-effective in terms of 326 
reducing antibiotic prescribing, and the intervention may offer a cost-effective way of 327 
preserving the effectiveness of the available antibiotics in an era where pharmaceutical 328 
companies are not successfully channelling enough resources into their development.2 329 
Training GPs in advanced, relevant communication skills might also help to preserve the 330 
effectiveness of new antibiotics if and when they become available. Prescribing antibiotics to 331 
patients who are likely to benefit is one of the aims of the UK government’s five-year 332 
strategy on antibiotics44 and the widespread use of advanced, specific communication skills is 333 
likely to help achieve this aim since the intervention is both effective and cost-effective in 334 
terms of reducing antibiotic prescribing.  335 
Compared to usual care, CRP was also found to be cost-effective. Thus, CRP represents a 336 
more cost-effective means of reducing unnecessary antibiotic prescribing compared to usual 337 
care. However, this was not as cost-effective as communication skills. The National Institute 338 
for Health and Care Excellence (NICE) in the UK and Nederlands Huisartsen Genootschap 339 
(NHG) in the Netherlands have recommended that point of care CRP testing should be 340 
considered for patients presenting with symptoms of LRTI if it is not clear whether 341 
antibiotics should be prescribed.45-46 Similarly, Belgium has implemented training in 342 
communication skills at the national level. However, if governments and policy makers 343 
choose to adopt these interventions, the current cost of implementing them on a large scale 344 
needs to be considered.  The other issue that needs to be considered is whether the 345 
widespread use of testing will ‘medicalise’ largely self-limiting illnesses – by creating the 346 
perception that consulting for a test is necessary to decide whether treatment is necessary -  347 
and thus increase consultations, potentially reducing efficiency and limiting the ability to 348 
reduce antibiotic prescribing.47 349 
The interventions considered in this study (communication skills and CRP) are primarily 350 
aimed at reducing the prescription of antibiotics by GPs and a potential question is whether 351 
the QALY, which is focused primarily on measuring health gain, should be the main outcome 352 
measure for interventions of this type. Whilst withholding antibiotics may lead to a reduction 353 
in health in the short-run,20 this may be considered acceptable in the context of prescribing 354 
antibiotics for future use, with the subsequent future health gain for the individual and society 355 
that implies. It is therefore suggested that the impact of antibiotic resistance should be 356 
accounted for in all economic evaluations of interventions that consider antibiotic use. Our 357 
study attempted to account for this by including a cost of resistance in the analysis and this 358 
clearly had a significant impact on the results that we obtained. The implication of not 359 
accounting for resistance is that policy makers may be led to believe that such an intervention 360 
may not provide value for money and not implement interventions that do not appear cost-361 
effective because the resistance costs are excluded. However, there are clear benefits to 362 
society when antibiotic prescribing is reduced. This study recommends that future research 363 
should focus on how to capture and include the cost of resistance in economic evaluations.   364 
In conclusion, internet-based training in communication skills is a cost-effective intervention 365 
to reduce antibiotic prescribing for respiratory tract infections in primary care if the cost of 366 
antibiotic resistance is accounted for.    367 
 368 
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TABLE 1: Source of valuation data and country contribution to sample size 
 Belgium Netherlands Poland Spain UK 
GP  Visits 1 1 1 1 2 
Nurse Visits N/A 1 1 1 2 
Out of hours GP 9 9 9 9 2 
Walk in centre N/A 1 1 1 1 
Hospital Admissions 1 1 1 1 8 
Investigations 9 9 9 9 8 
Medication 6 5 1,9 3,1 4 
Contribution to sample size 318 (7.5%) 329 (7.7%) 1419 (33.3%) 1318 (30.9%) 880 (20.6%) 
 
1= Previous study, 2= Curtis L (www.pssru.ac.uk), 3= www.vademecum.es, 4= British National Formulary (www.bnf.org), 5= Dutch healthcare 
insurance board (www.medicijnkosten.nl), 6= www.bcfi.be, 7= www.http://riziv.fgov.be, 8= NHS Reference costs 9= Market basket approach  
 
 
 
 
 
TABLE 2: Mean (SD) Resource use for complete case analysis 
 Usual care (n=515) CRP no Comm (n=660) Comm no CRP (n=740) CRP comm  
(n=709) 
PRIMARY CARE VISITS [Mean (SD)] 
GP visits 0.194 (0.472) 0.355 (0.762) 0.284 (0.713) 0.236 (0.596) 
Nurse Visits 0.016 (0.206) 0.045 (0.323) 0.103 (0.741) 0.039 (0.263) 
Out hours GP visits 0.015 (0.271) 0.006 (0.095) 0.023 (0.182) 0.016 (0.163) 
SECONDARY CARE VISTIS [Mean (SD)] 
Hospital emergency visits 0.002 (0.044) 0.003 (0.054) 0.018 (0.134) 0.016 (0.155) 
Walk in centre visits 0.004 (0.087) 0.002(0.039) 0.022 (0.186) 0.035 (0.383) 
Specialist visits 0.004 (0.062) 0.018 (0.155) 0.028 (0.222) 0.023 (0.218) 
Admissions 0.010 (0.182) 0.026 (0.379) 0.019 (0.320) 0.030 (0.394) 
PRESCRIPTIONS n (%) 
Antibiotic prescription 307 (59.61%) 222 (33.64%) 303 (40.95%) 242 (34.13%) 
Over the counter medication 346 (67.18%) 419 (63.48%) 451 (60.95%) 441 (62.20%) 
CRP test 12 (2.33%) 441 (66.82%) 57 (7.70%) 461 (65.02%) 
 
 
 
 
 
 
 
 
 
 
TABLE 3: Costs (Complete case analysis) (€) 
 Usual care (n=515) CRP no Comm (n=660) Comm no CRP (n=740) CRP comm  
(n=709) 
PRIMARY CARE VISITS 
GP visits €3.44 (10.27) €4.68 (11.23) €4.60 (13.90) €3.65 (10.12) 
Nurse Visits €0.22 (3.12) €0.32 (3.01) €1.36 (9.95) €0.49 (4.71) 
Out hours GP visits €5.30 (92.83) €2.04 (32.27) €8.07 (63.65) €5.36 (56.01) 
SECONDARY CARE VISTIS 
Hospital emergency visits €0.27 (6.22) €0.41 (7.48) €2.60 (18.73) €2.16 (21.30) 
Walk in centre visits €0.09 (2.03) €0.03 (0.90) €0.52 (4.52) €0.78 (7.90) 
Specialist visits €0.84 (13.54) €3.75 (31.70) €5.58 (44.60) €4.83 (46.70) 
Admissions €4.78 (89.56) €12.20 (179.20) €9.08 (150.58) €13.92 (186.81) 
OTHER COSTS 
Prescription €11.96 (26.87) €8.74 (19.32) €9.79 (19.04) €11.99 (34.64) 
OTC medication €6.55 (17.36) €4.48 (12.95) €4.52 (12.65) €6.18 (17.32) 
CRP test €0.19 (1.23) €5.24 (3.74) €0.28 (1.07) €4.88 (3.79) 
Trial intervention costa €0 €11.42 (7.45) €5.62 (3.69) €13.43 (8.53) 
Resistance cost €105.39 (94.01) €57.29 (84.86) €66.09 (84.49) €60.34 (88.02) 
 
a Cost associated with delivering the trial interventions  
 
 
 
 
 
 
 
TABLE 4: Mean EQ-5D scores over 4 weeks and antibiotic prescribing (Complete cases) 
 Usual care (n=515) CRP no Comm (n=660) Comm no CRP (n=740) CRP comm  
(n=709) 
EQ-5D 
Day 1 0.717 (0.216) 0.729 (0.212) 0.693 (0.228) 0.710 (0.223) 
Week 1 0.816 (0.197) 0.817 (0.207) 0.786 (0.214) 0.792 (0.210) 
Week 2 0.884 (0.176) 0.881 (0.182) 0.864 (0.185) 0.869 (0.186) 
Week 3 0.898 (0.170) 0.899 (0.176) 0.894 (0.176) 0.893 (0.174) 
Week 4 0.906 (0.165) 0.907 (0.169) 0.903 (0.168) 0.899 (0.169) 
Antibiotic prescribing 
Antibiotic Prescribing  0.596 (0.491) 0.336 (0.473) 0.409 (0.492) 0.341 (0.474) 
 
 
TABLE 5: Overall and country‐specific cost‐effectiveness (Cost‐utility analysis) 
         
 Costa QALY ICER ICER (compared 
to UC) 
Overall (n=4264) 
CRP&Comm 94.36 0.0648 Dominated by Comm Dominated by UC 
Usual care 92.46 0.065 Dominated by Comm N/Af 
CRP 87.41 0.0651 Dominated by Comm Dominates UC 
Comm 83.21 0.0651 N/Af Dominates UC 
     
Belgium (n=318) 
Comm 93.28 0.0651 3450e 7120b 
CRP&comm 92.59 0.0649 7343c 8038b 
CRP 87.45 0.0642 12900b 12900b 
Usual care 86.16 0.0641 N/Af N/Af 
     
Netherlands (n=329) 
CRP&Comm 84.99 0.0649 Dominated by CRP Dominated by UC 
Usual care 75.52 0.065 Dominated by CRP N/Af 
CRP 73.41 0.0656 27,186c Dominates UC 
Comm 54.38 0.0649 N/Af N/A 
    
Poland (n=1419) 
Usual care 143.41 0.0663 49129c N/Af 
Comm 114.37 0.0656 Dominated by CRP 41486g 
CRP&Comm 110.95 0.0652 Dominated by CRP 29509g 
CRP 109.02 0.0656 N/Af 49129g 
    
Spain (n=1318) 
CRP&Comm 78.71 0.0648 Dominated by Usual care Dominated by UC 
CRP 70.86 0.0656 Dominated by Usual care Dominated by UC 
Usual care 66.46 0.0659 1000d N/Af 
Comm 65.86 0.0653 N/Af 1000g 
     
UK (n=880) 
CRP&Comm 106.57 0.0641 Dominated by Comm 25050b 
Usual care 101.56 0.0639 Dominated by Comm N/Af 
CRP 98.75 0.0645 Dominated by Comm Dominates UC 
Comm 98.05 0.0648 N/Af Dominates UC 
    
a Costs includes the costs associated with antibiotic resistance b Compared to usual care    c Compared 
to CRP training d Compared to communication skills training e Compared to training in both CRP 
testing and communication skills f not applicable, this is the  reference case           g ICER value 
represents a comparison of usual care versus the respective intervention since the ICER generated 
from a comparison of the respective intervention with usual care represents a willingness to accept a 
loss in benefit, rather than a willingness to pay for a gain in benefit.   UC=usual care
TABLE 6: Overall and country‐specific cost‐effectiveness (Cost‐effectiveness analysis) 
 
Costa Outcome ICER 
ICER (compared 
to UC) 
Overall (n=4264) 
CRP + Comm 60.32 0.8003 338.8889b 126.209b 
CRP 49.34 0.7679 176.5343d 95.44643b 
Comm 39.56 0.7125 68.8019b 68.8019b 
Usual care 27.96 0.5439 N/Af N/A
f 
    
Belgium (n=318) 
CRP + Comm 62 0.8216 323.4528b 234.3308b 
CRP 52.07 0.7909 26.85393d 203.7946b 
Comm 49.68 0.7019 26350b 26350b 
Usual care 33.81 0.7013 N/Af N/A
f 
    
Netherlands (n=329) 
CRP + Comm 58.47 0.8409 1929.73c 126.6091b 
CRP 44.19 0.8335 72.67583b 72.67583b 
Usual care 26.21 0.5861 Dominated by Comm N/A
f 
Comm 26 0.7894 N/Af Dominates UC 
    
Poland (n=1419) 
CRP + Comm 61.3 0.7366 189.8754c 81.94658b 
CRP 49.11 0.6724 92.14953d 55.44933b 
Comm 44.18 0.6189 46.00962b 46.00962b 
Usual care 34.61 0.4109 N/Af N/A
f 
    
Spain (n=1318) 
CRP + Comm 47.5 0.8044 Dominated by CRP 162.4065b 
CRP 39.53 0.8156 145.0094d 100.5685b 
Comm 31.83 0.7625 78.13688b 78.13688b 
Usual care 23.61 0.6573 N/Af N/A
f 
    
UK (n=880) 
CRP + Comm 74.46 0.8066 202.439c 112.511b 
CRP 59.52 0.7328 170.1754d 95.16466b 
Comm 49.82 0.6758 82.03317b 82.03317b 
Usual care 23.11 0.3502 N/Af N/A
f 
    
a Costs excludes the costs associated with antibiotic resistance b Compared to usual care    c Compared 
to CRP training d Compared to communication skills training e Compared to training in both CRP 
testing and communication skills f not applicable, this is the reference case UC=usual care
Figure 1: Cost-effectiveness plane (cost-utility analysis) 
 
Figure 2: Cost‐effectiveness acceptability frontier (cost‐utility analysis) 
 
  
 
 
 
 
